Literature DB >> 11452867

Prevalence of colonisation and resistance patterns of vancomycin-resistant enterococci in healthy, non-hospitalised persons in Switzerland.

F Balzereit-Scheuerlein1, R Stephan.   

Abstract

In order to obtain data about the prevalence and the resistance profiles of vancomycin-resistant enterococci (VRE) in the community, we investigated fecal samples of employees (n = 1026) from food processing companies of different Swiss cantons. The susceptibility of the isolated VRE-strains against penicillin, ampicillin, tetracyclin, ciprofloxacin, chloramphenicol, streptomycin and gentamicin as well as the minimal inhibitory concentrations (MIC) for vancomycin and teicoplanin were determined by agar diffusion and microbroth dilution, respectively. The type of vancomycin-resistance (vanA, vanB, vanC1, -C2 or -C3) was confirmed by polymerase chain reaction (PCR). A ratio of 50 samples out of 1026 (4.9%) was found VRE-positive, all of the isolated strains carried the vanA-resistance gene. Compared to recent publications from other European countries, these results represent a rather high prevalence of VRE-carriers in the community.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452867     DOI: 2001/19/smw-06072

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  2 in total

1.  Colonization With Multidrug-Resistant Organisms Among Healthy Adults in the Community Setting: Prevalence, Risk Factors, and Composition of Gut Microbiome.

Authors:  Yu-Shan Huang; Liang-Chuan Lai; Yu-An Chen; Kuan-Yin Lin; Yi-Hsuan Chou; Hsiu-Chi Chen; Shu-Sheng Wang; Jann-Tay Wang; Shan-Chwen Chang
Journal:  Front Microbiol       Date:  2020-06-24       Impact factor: 5.640

2.  Molecular detection of vanA and vanB genes among vancomycin-resistant enterococci in ICU-hospitalized patients in Ahvaz in southwest of Iran.

Authors:  Mojtaba Moosavian; Hosein Ghadri; Zahra Samli
Journal:  Infect Drug Resist       Date:  2018-11-15       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.